Oruka Therapeutics (ORKA) Gains from Investment Securities (2011 - 2026)
Oruka Therapeutics' quarterly Gains from Investment Securities came in at $1.5 million in Q1 2026, up 2371.58% year-on-year from $60000.0 in Q1 2025, and up 209.69% quarter-over-quarter from -$1.4 million in Q4 2025.
Oruka Therapeutics has reported Gains from Investment Securities for 16 years, with the latest figure at $1.5 million in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities rose 2371.58% year-over-year to $1.5 million; the trailing twelve-month figure through Mar 2026 stood at $1.5 million (up 8338.62% YoY), and the FY2025 full-year result was $4.0 million, up 152.01% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at $1.5 million, up from -$1.4 million in the prior quarter.
- The five-year high for Gains from Investment Securities was $2.1 million in Q2 2025, with the low at -$1.4 million in Q4 2025.
- Average Gains from Investment Securities over 5 years is $393421.9, with a median of $88174.0 recorded in 2023.
- Year-over-year, Gains from Investment Securities surged 5064.85% in 2023 and slumped 97.52% in 2025.
- Tracing ORKA's Gains from Investment Securities over 5 years: stood at $186891.0 in 2022, then jumped by 229.98% to $616707.0 in 2023, then surged by 108.81% to $1.3 million in 2024, then sank by 204.99% to -$1.4 million in 2025, then soared by 209.69% to $1.5 million in 2026.
- The last three Gains from Investment Securities figures came in at $1.5 million (Q1 2026), -$1.4 million (Q4 2025), and $32000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Oruka Therapeutics | 3.04 Bn | 2.65 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.48 Mn |
| Mar 31, 2026 | 1.48 Mn |
| Dec 31, 2025 | -1.35 Mn |
| Dec 31, 2025 | -1.35 Mn |
| Sep 30, 2025 | 32,000.00 |
| Sep 30, 2025 | 32,000.00 |
| Jun 30, 2025 | 2.10 Mn |
| Jun 30, 2025 | 2.10 Mn |
| Mar 31, 2025 | 60,000.00 |
| Mar 31, 2025 | 60,000.00 |
| Sep 30, 2024 | 1.29 Mn |
| Sep 30, 2024 | 1.29 Mn |
| Jun 30, 2024 | 45,652.00 |
| Jun 30, 2024 | 45,652.00 |
| Mar 31, 2024 | 645,845.00 |
| Mar 31, 2024 | 645,845.00 |
| Dec 31, 2023 | 616,707.00 |
| Dec 31, 2023 | 616,707.00 |
| Sep 30, 2023 | 88,174.00 |
| Sep 30, 2023 | 88,174.00 |
| Jun 30, 2023 | 619,782.00 |
| Jun 30, 2023 | 619,782.00 |
| Mar 31, 2023 | 40,103.00 |
| Mar 31, 2023 | 40,103.00 |
| Sep 30, 2022 | 186,891.00 |
| Sep 30, 2022 | 186,891.00 |
| Jun 30, 2022 | 12,000.00 |
| Jun 30, 2022 | 12,000.00 |
| Mar 31, 2022 | 34,663.00 |
| Mar 31, 2022 | 34,663.00 |
| Dec 31, 2021 | -78,000.00 |
| Dec 31, 2021 | -78,000.00 |
| Sep 30, 2021 | 170,200.00 |
| Sep 30, 2021 | 170,200.00 |
| Jun 30, 2021 | 147,200.00 |
| Jun 30, 2021 | 147,200.00 |
| Mar 31, 2021 | 596,497.00 |
| Mar 31, 2021 | 596,497.00 |
| Sep 30, 2020 | 37,138.00 |
| Sep 30, 2020 | 37,138.00 |
| Jun 30, 2020 | 246.00 |
| Jun 30, 2020 | 246.00 |
| Mar 31, 2020 | 246.00 |
| Mar 31, 2020 | 246.00 |
| Dec 31, 2019 | 33,000.00 |
| Dec 31, 2019 | 33,000.00 |
| Sep 30, 2019 | 32,683.00 |
| Sep 30, 2019 | 32,683.00 |
| Jun 30, 2019 | 670.00 |
| Jun 30, 2019 | 670.00 |
| Mar 31, 2019 | 222.00 |
| Mar 31, 2019 | 222.00 |
| Sep 30, 2018 | 40,000.00 |
| Sep 30, 2018 | 40,000.00 |
| Jun 30, 2018 | 625,399.00 |
| Jun 30, 2018 | 625,399.00 |
| Mar 31, 2018 | 10,042.00 |
| Mar 31, 2018 | 10,042.00 |
| Dec 31, 2017 | 1,000.00 |
| Dec 31, 2017 | 1,000.00 |
| Sep 30, 2017 | 278,642.00 |
| Sep 30, 2017 | 278,642.00 |
| Jun 30, 2017 | 277,604.00 |
| Jun 30, 2017 | 277,604.00 |
| Mar 31, 2017 | 826,617.00 |
| Mar 31, 2017 | 826,617.00 |
| Dec 31, 2016 | -303,000.00 |
| Dec 31, 2016 | -303,000.00 |
| Sep 30, 2016 | 18,713.00 |
| Sep 30, 2016 | 18,713.00 |
| Jun 30, 2016 | 584,865.00 |
| Jun 30, 2016 | 584,865.00 |
| Mar 31, 2016 | 7,000.00 |
| Mar 31, 2016 | 7,000.00 |
| Dec 31, 2015 | -229,000.00 |
| Dec 31, 2015 | -229,000.00 |
| Sep 30, 2015 | 170,545.00 |
| Sep 30, 2015 | 170,545.00 |
| Jun 30, 2015 | 137,380.00 |
| Jun 30, 2015 | 137,380.00 |
| Mar 31, 2015 | 203,920.00 |
| Mar 31, 2015 | 203,920.00 |
| Dec 31, 2014 | 93,000.00 |
| Dec 31, 2014 | 93,000.00 |
| Sep 30, 2014 | 1.04 Mn |
| Sep 30, 2014 | 1.04 Mn |
| Jun 30, 2014 | 3,506.00 |
| Jun 30, 2014 | 3,506.00 |
| Mar 31, 2014 | 1.04 Mn |
| Mar 31, 2014 | 1.04 Mn |
| Dec 31, 2013 | 120,433.00 |
| Dec 31, 2013 | 120,433.00 |
| Sep 30, 2013 | 731,535.00 |
| Sep 30, 2013 | 731,535.00 |
| Jun 30, 2013 | 6,314.00 |
| Jun 30, 2013 | 6,314.00 |
| Mar 31, 2013 | 6,259.00 |
| Mar 31, 2013 | 6,259.00 |
| Dec 31, 2012 | 144,019.00 |
| Dec 31, 2012 | 144,019.00 |
| Sep 30, 2012 | 875,953.00 |
| Sep 30, 2012 | 875,953.00 |
| Jun 30, 2012 | 864,238.00 |
| Jun 30, 2012 | 864,238.00 |
| Dec 31, 2011 | -12,000.00 |
| Dec 31, 2011 | -12,000.00 |
| Sep 30, 2011 | 1,000.00 |
| Sep 30, 2011 | 1,000.00 |
| Mar 31, 2011 | -5,000.00 |
| Mar 31, 2011 | -5,000.00 |